RxDoctor Payments Data

Steven Simon, MD

Cardiovascular Disease · Aurora, CONPI 1346583259

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Kaneka Medical America LLC at 34.3% of the total. 2024 is the largest year on record at $290, 4.1 times the $71 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in CO, where the typical reported total is $1,537.

$611in general payments, 2019–2025

Across 9 payments — averaging $67.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kaneka Medical America LLC$210
  • Kowa Pharmaceuticals America, Inc.$127
  • Regeneron Healthcare Solutions, Inc.$102
  • Regeneron$80
  • Heartflow, Inc.$44
  • Amgen$27
  • plus $20 from 1 others
$167,539in research payments, 2019–2025

Across 17 payments — averaging $9855.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cleerly, Inc.$119K
  • Amgen$48K

What the payments were for

  • Food & beverage$611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$611 in reported general payments places this provider in the 35th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$111,631
Medicare patients
2,398
Services billed
3,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$127,283
Repatha SureclickEvolocumab96$122,553
JardianceEmpagliflozin25$32,243
EntrestoSacubitril/Valsartan26$30,520
XareltoRivaroxaban21$28,174
FarxigaDapagliflozin Propanediol21$24,280
Praluent PenAlirocumab16$17,543
NexletolBempedoic Acid25$14,918
BrilintaTicagrelor12$7,722
Ezetimibe161$5,182
Metoprolol Succinate207$2,962
Rosuvastatin Calcium192$2,888
Atorvastatin Calcium235$2,505
Losartan Potassium105$1,072
Amlodipine Besylate131$664

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →